about
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxinProtective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcerGlobally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone FGenomics of Actinobacteria: tracing the evolutionary history of an ancient phylumSpatial dependency of Buruli ulcer prevalence on arsenic-enriched domains in Amansie West District, Ghana: implications for arsenic mediation in Mycobacterium ulcerans infectionClinical and Laboratory Diagnosis of Buruli Ulcer Disease: A Systematic ReviewActivities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in miceIn-vitro activity of avermectins against Mycobacterium ulceransSterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in MiceMycobacterial phylogenomics: an enhanced method for gene turnover analysis reveals uneven levels of gene gain and loss among species and gene familiesMycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer.Analysis of Mycobacterium species for the presence of a macrolide toxin, mycolactone.Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report.Prevalence of Buruli ulcer in Akonolinga health district, Cameroon: results of a cross sectional survey.Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana.Environmental and Behavioral Drivers of Buruli Ulcer Disease in Selected Communities Along the Densu River Basin of Ghana: A Case-Control Study.Under treated necrotizing fasciitis masquerading as ulcerated edematous Mycobacterium ulcerans infection (Buruli ulcer).All-oral antibiotic treatment for buruli ulcer: a report of four patients.Activities of several antimicrobials against Mycobacterium ulcerans infection in mice.Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.Evaluation of the medicinal use of clay minerals as antibacterial agents.Evaluation of a low-cost calorimetric approach for rapid detection of tuberculosis and other mycobacteria in culture.Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice.Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors.Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort studyBactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in miceIllness meanings and experiences for pre-ulcer and ulcer conditions of Buruli ulcer in the Ga-West and Ga-South Municipalities of Ghana.Contribution of the community health volunteers in the control of Buruli ulcer in Bénin.Histopathologic features of Mycobacterium ulcerans infection.Screening of antifungal azole drugs and agrochemicals with an adapted alamarBlue-based assay demonstrates antibacterial activity of croconazole against Mycobacterium ulcerans.Ecological niche modelling of Hemipteran insects in Cameroon; the paradox of a vector-borne transmission for Mycobacterium ulcerans, the causative agent of Buruli ulcer.Mycobacterium ulcerans Disease with Unusual Sites Not to Be IgnoredMycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.Persisting social participation restrictions among former Buruli ulcer patients in Ghana and Benin.Perceptions on the effectiveness of treatment and the timeline of Buruli ulcer influence pre-hospital delay reported by healthy individualsTowards rational use of antibiotics for suspected secondary infections in Buruli ulcer patientsHeterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence.In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.Analysis of an IS2404-based nested PCR for diagnosis of Buruli ulcer disease in regions of Ghana where the disease is endemic.
P2860
Q24186073-46A733E2-BBC7-46CC-BDD6-8A16F23651BFQ24524154-51213568-6448-40DE-8502-33C49A4450ADQ24548647-1AF5D683-1882-427D-9DAC-2FFCA5E1D66DQ24673638-ADDC9593-204A-42EB-A42B-7A705D5539DAQ24681753-FA47D297-A630-4D1A-8E97-A4511A561711Q24800183-2DCBDCB6-07FB-49FB-B0C2-544E556A1BFCQ26740428-1042641C-3A8F-4247-BC2A-159079B71723Q28476689-E20C346C-E0D3-4FF3-8F30-C1F7B192B3FFQ28543887-D8B1643B-2E90-44C8-B970-E89F19D6AE21Q28552736-8A7A3127-3772-44C5-BA05-93FD8AD6FF89Q30582508-1D6924D4-A611-42D9-8FBE-DE877D9EEC90Q30914398-91D42DE6-2FF2-48EB-BBAC-C093E72FB0A8Q33196152-BDCC308A-897E-4B28-94E7-A6C693C48C93Q33331051-7BD2DE68-2843-4733-BEDC-EE33EA71445EQ33472707-C3E94149-D2CD-4346-BE2C-48DD7B991A08Q33593952-3F4AE37D-F3D5-490B-A564-3823254099A4Q33636819-EA0CCF31-F0F5-4015-B7B2-81C65C9F1069Q33693677-8F59EDBA-9ADE-413F-871C-A184D34FBCA3Q33769921-34663885-1756-4A34-9DFF-873E36313590Q33980444-93FB0D4C-836C-4920-A6EE-FB61A6BBC8B5Q33983346-3ACDDDBB-395A-40F0-ACBB-6D70855B3178Q33995558-28A10ED8-FCB1-486F-832E-10BBC1CCB37FQ34027889-FAA699C9-617A-4B67-A07C-5E31779F709BQ34033119-44A46FF8-D01F-4C37-A8C3-413BEB7C2B7AQ34084883-AC8B1CD7-FD9E-42C0-B0A8-C325ED77FFCBQ34137837-C7D805C3-7D9F-413E-A442-1614AB5D6CA1Q34144367-A78FF917-EE71-4CA7-8AFF-FC9CCB21DE6EQ34218700-81DBFE05-7CBA-434B-9CB8-7F0B7DDB3C3DQ34281971-57D71DC5-2B02-49C1-A7EF-72E4A8CA3C6AQ34396322-D6BB53AB-32C3-4743-98B4-3D3A512EFFD3Q34420330-69CDC35D-6016-42F2-89FA-B3742CC84A58Q34423302-9721F65F-4354-4FAC-98E5-03BC6564F6BAQ34438022-34FE96EE-90F0-4510-9828-CE06889A63CEQ34484489-67C8DC22-2835-430E-9C38-4F7E383BB525Q34505664-38006C82-4722-4E97-87DE-F27D138E6B06Q34563653-5E27A2E5-D596-42A4-85E3-5F696FE049B6Q34566628-DE8F4D54-BDE8-415E-BF6A-3F9DA28DD160Q34581754-62EE108F-17F7-4907-87C8-B68D9ACE43F3Q34680628-311E0AF5-504B-4DD6-9E9B-2DEB79B96434Q34750009-54356368-577B-48AD-B1A6-F3A186088ADC
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Mycobacterium ulcerans infection.
@ast
Mycobacterium ulcerans infection.
@en
type
label
Mycobacterium ulcerans infection.
@ast
Mycobacterium ulcerans infection.
@en
prefLabel
Mycobacterium ulcerans infection.
@ast
Mycobacterium ulcerans infection.
@en
P2093
P1433
P1476
Mycobacterium ulcerans infection
@en
P2093
J W Tappero
W T van der Graaf
P304
P356
10.1016/S0140-6736(99)01156-3
P407
P577
1999-09-01T00:00:00Z